Through the Community Research Fund Program, the Oligodendroglioma Research Fund supports promising research specifically targeted at creating new treatments for oligodendroglioma (oligo) while leveraging our scientific expertise and proven processes.
To identify the areas of research that would hold the most promise to improve patient care and treatment, we have convened a panel of the leading oligo researchers to form an expert Advisory Council to guide the grant process, and help ensure scientific success. Chaired by visionaries Dr. Gregory Cairncross, Professor and Head of the Department of Clinical Neurosciences at the University of Calgary, and G. Yancey Gillespie, PhD at University of Alabama at Birmingham, the group identified three specific areas of focus:
- Stem cell and lineage biology
- Tumor modeling
The Oligo Advisory Council performs a rigorous review of each grant application to select the projects that best meet the needs of the current oligo research landscape. Recipients receive a restricted grant of $300,000 over two years to fund their projects. Oligo Research Fund grant recipients are:
David Louis, MD, Harvard Medical School, Massachusetts General Hospital
Mapping the epigenomic landscape of oligodendroglioma to elucidate tumor growth and chemosensitivity
Anders Persson, PhD, University of California, San Francisco
IDH1R132H-induced transformation of oligodendrocyte progenitor cells into oligodendroglioma
Both researchers will lead projects that seek to determine what causes Oligo tumors to develop and subsequently grow through next-generation sequencing (Louis), and tumor modeling (Persson), so that future investigations can better understand what biomarkers to target with potential therapies. See the full announcement on these projects.
CONTRIBUTING TO THE FUND
Through the Community Research Fund model, the Oligo Research Fund allows contributors to pool their donations into one fund dedicated to oligo research. For information about contributing to the Oligo Research Fund please contact 617-924-9997.